Dublin, Ireland, January 13th, 2010 – ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr. Bob Scott-Edwards has retired from the position of President, ICON Central Laboratories, effective December 31st 2009. Mr. Tom O’Leary, previously Senior Vice President and Global Head of Data Management, ICON Clinical Research, has succeeded Mr. Scott-Edwards.
Mr. Scott-Edwards has served as President, ICON Central Laboratories, since August 2004, having previously held the position of Vice President, Sales & Marketing at ICON Central Laboratories since June 2000. Under his tenure, ICON established a global network of wholly-owned central laboratories in New York, Dublin, Ireland, Singapore and Bangalore, India and has provided laboratory services to thousands of clients in virtually every phase and therapeutic area of clinical development.
“Bob has been instrumental in establishing ICON as a leading global provider of central laboratory services and has been a key member of ICON’s executive management team,” commented Peter Gray, CEO at ICON plc. “His dedication to quality and commitment to serving our clients has been outstanding and I wish him a long and fulfilling retirement. I would also like to wish Tom every success in his new role as we look to continue to grow our central laboratory business.”
Mr. Tom O’Leary joined ICON in February, 2001 and was appointed Global Head of Data Management in 2006. Prior to ICON, Mr. O’Leary held senior data management, project management and resource management positions at SmithKline Beecham and GlaxoSmithKline. He is a graduate of Kingston University in Surrey and a Member of the Royal Society of Chemistry. He holds a Degree in Medicinal Chemistry and a Masters in Data Management.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has about 7,000 employees, operating from 68 locations in 38 countries.